- Investopedia•3 hours ago
Biogen’s spinoff Bioverativ remains on track for public listing in early 2017, and gets two key hemoglobinopathy programs from Sangamo.
- Investopedia•4 hours ago
Biogen’s multiple sclerosis drug Tecfidera, which accounts for one-third of the company’s revenue, is up for a patent challenge.
BIIB : Summary for Biogen Inc. - Yahoo Finance
Biogen Inc. (BIIB)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||296.81 x 100|
|Ask||296.86 x 100|
|Day's Range||293.05 - 299.95|
|52 Week Range||223.02 - 333.65|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||16.80|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|